SCHEMBL24529684

SCHEMBL24529684

COc1cc(Br)cc2c1ncn2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 3/20 0.41
▸ PDE10A Q9Y233 3/20 0.39
▸ PDE2A O00408 1/20 0.38
▸ PDE5A O76074 1/20 0.38
▸ PDE11A Q9HCR9 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PRNP P04156 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ GAA P10253 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ERN1 O75460 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ GRM5 P41594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34475643 1.00 NQO2 (0.41) NQO2PDE10APDE2APDE5APDE11A
SCHEMBL34474997 0.79 MAPT (0.42) ALDH1A1SMN1; SMN2PRNPMAPTGAA
SCHEMBL34475846 0.76 MAOB (0.43) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL30038679 0.76 HSP90AA1 (0.34) ALDH1A1SMN1; SMN2PRNPGAAMEN1
SCHEMBL5901433 0.75 ADORA2A (0.38) NQO2ALDH1A1GAAGRM5
SCHEMBL31286517 0.75 ADORA2A (0.38) NQO2ALDH1A1GAAGRM5
SCHEMBL31286514 0.75 ADORA2A (0.38) NQO2ALDH1A1GAAGRM5
SCHEMBL22125661 0.75 MEN1 (0.37) ALDH1A1GAAMEN1POLBKMT2A
SCHEMBL20600776 0.75 PRPS1 (0.44) NQO2ALDH1A1GAAGRM5
SCHEMBL31140528 0.74 CA12 (0.49) PRNPNPSR1KMT2AL3MBTL1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-03-28 — — US disclosed
WO-2022132696-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS HCRTR1, HCRTR2, UTS2R NQO2 1211/4885PDE10A 1142/4885PDE2A 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback